VertiFlex

42 articles about VertiFlex

• 

  Massachusetts Life Science M&A Hits $22.5 Billion So Far This Year

  7/10/2019

  As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.

• H.I.G. BioHealth Partners Completes Sale of Vertiflex to Boston Scientific

  6/18/2019

  H.I.G. BioHealth Partners recently announced the sale of Vertiflex, Inc. to Boston Scientific for a total equity value of approximately $465 million in cash and additional payments contingent on the Company attaining certain commercial goals.

• Boston Scientific Closes Acquisition Of Vertiflex, Inc.

  6/11/2019

   Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Vertiflex, Inc., a privately-held company that developed and commercialized the Superion® Indirect Decompression System, a minimally-invasive device used to improve physical function and reduce pain in patients with lumbar spinal stenosis (LSS) – the narrowing of the spinal canal, which can cause compression of nearby nerves.

• Boston Scientific Announces Agreement To Acquire Vertiflex, Inc.

  5/9/2019

  Acquisition of lumbar spinal stenosis treatment to expand portfolio of interventional pain therapies

• Latham & Watkins Advises Boston Scientific in its Acquisition of Vertiflex

  5/9/2019

  Boston Scientific (NYSE: BSX) has announced that it has entered into a definitive agreement to acquire Vertiflex, Inc., a privately-held company which has developed and commercialized the Superion® Indirect Decompression System,

• Vertiflex® Announces Publication of Data Analysis Showing 85% Reduction in Patients Using Opioids After Treatment With Superion® Indirect Decompression System

  11/20/2018

  Study published in Journal of Pain Research has important public health implications given current opioid epidemic in the U.S.

• Vertiflex Announces Appointments to Board of Directors, Ray Baker, MD, and Richard Mott

  6/5/2018

  Company milestones demonstrate progress and commercial success of product portfolio

• VertiFlex Appoints Michael Enxing To Vice President, Chief Commercial Officer

  7/13/2017

• VertiFlex Announces Two Significant Reimbursement Milestones To Expand Market Opportunity For Superion Interspinous Spacer

  11/10/2015

• MCRA Assists VertiFlex With Obtaining FDA PMA Approval For The Superion Interspinous Spacer System

  6/25/2015

• VertiFlex Announces FDA PMA Approval For The Superion Interspinous Spacer

  5/26/2015

• VertiFlex Announces FDA Advisory Panel Support For The Superion Interspinous Spacer

  2/23/2015

• VertiFlex Announces FDA Advisory Panel Meeting For The Superion® Interspinous Spacer System

  12/12/2014

• FDA Postpones Panel Meeting For VertiFlex's Superion Spine Device

  12/10/2014

• VertiFlex Scores FDA Panel Date For Superion Interspinous Spacer

  9/24/2014

• VertiFlex Announces First Study Patients Treated In Approved Coverage With Evidence Development Trial For Lumbar Spinal Stenosis

  8/28/2014

• VertiFlex Announces Publication of Superion® IDE Trial Results

  7/16/2014

• VertiFlex Announces Submission Of Final PMA Module To The FDA, For The Superion® Interspinous Spacer System

  4/1/2014

• VertiFlex Announces Decision By The Centers for Medicare & Medicaid Services

  1/14/2014

• VertiFlex Announces First Patient Successfully Treated With the Totalis™ Direct Decompression System

  3/18/2013